1,088.00
+4.02%
Close of 9 Nov 2026, in ILA
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About InterCure
Its shares trade on Tel Aviv under the ticker INCR.TA. It has been listed since 26 July 2007. In the fiscal year to 31 December 2024, it reported revenue of ILS 238.8m and a net loss of ILS 67.8m.
InterCure Ltd. operates as an investment holding company, with interests in the medical cannabis, biomedicine, life sciences, technology, and medical devices fields. The company is engaged in the production and sale of RESPeRATE, a Food and Drug Administration approved, non-drug, non-invasive hypertension treatment device. The Company’s patented device-guided breathing platform is used by RESPeRATE, and it enables a systematic reduction in sympathetic outflow of the autonomous nervous system, one of the key underlining causes for cardiovascular disease, insomnia and multiple other conditions. The firm operates a marketing office in London and outsourced call centers and warehouses in the United States, the United Kingdom, Germany and Canada.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 26 Jul 2007
- Employees
- 75
Leadership
Pay as last reported
- Mr. Ehud BarakChairman of the Board, since 2018
- Mr. Alexander RabinovitchChief Executive Officer, Director, since 2018
- Mr. Amos CohenChief Financial Officer
- Mr. Rami LevyChief of Operation - Canndoc’s
- Mr. Ori MimonCo-Chief Executive Officer of Cannolam Ltd
- Adv. Asaf OhyaonCo-Chief Executive Officer of Cannolam Ltd
- Mr. Alon GranotDirector
- Ms. Lennie Grinbaum MichelsonExternal Director
- Mr. Gideon HirschfeldExternal Director
- Mr. David SaltonIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- InterCure Ltd has a strong market presence and brand recognition in the healthcare industry.
- The company is backed by a highly skilled and experienced management team.
- InterCure has a diverse product portfolio, catering to different segments of the healthcare market.
Weaknesses
- InterCure faces stiff competition from other established players in the market.
- The company's reliance on a few key suppliers puts it at risk of supply chain disruptions.
- InterCure's geographic presence is limited to a few regions, hindering its global expansion opportunities.
Opportunities
- InterCure can leverage advancements in technology to develop innovative healthcare solutions.
- The growing demand for healthcare services presents an opportunity for InterCure to expand its customer base and market share.
- Strategic partnerships and collaborations can help InterCure penetrate new markets and reach a wider audience.
Threats
- InterCure faces regulatory uncertainties, which could impact its product development and commercialization processes.
- Economic downturns and fluctuations in healthcare spending pose a threat to InterCure's financial performance.
- Competitive pricing and cost pressures in the healthcare industry can affect InterCure's profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.